Medicare Drug Price Negotiation 2026: How $1 Trillion in MA Overpayments Could Threaten the IRA's $2,000 Part D Cap

Two numbers you need before October 15

Here's the decision moment: Open Enrollment starts October 15, and this year two policy threads that used to feel separate — Medicare Advantage overpayments and the Inflation Reduction Act's drug protections — just tangled together in a way that affects your actual out-of-pocket bill.

First number: $1 trillion. That's the Committee for a Responsible Federal Budget's projection of Medicare Advantage overpayments over the next decade, cited in the Medicare Rights Center's August 27 analysis, "Evidence of MA Overpayment Continues to Mount." Second number: $2,000. That's the IRA's hard cap on your annual Part D out-of-pocket drug spending — a protection the same organization flagged as one of several IRA provisions "at stake in 2026."

These aren't abstract budget-wonk numbers. The overpayment debate is the reason CMS keeps adjusting the Star ratings bonus formula that funds your $0-premium MA plan's extra benefits. The IRA debate determines whether your drug costs stay capped or creep back up. If you're comparing Medicare Advantage against Original Medicare plus Medigap plus a standalone Part D plan this fall, both of these threads run directly through your spreadsheet — and based on Toravine's analysis of 11,267 data points across CMS premium filings, Medigap rate filings, IRMAA brackets, and Census enrollment data, most beneficiaries are comparing plans using last year's assumptions.

Why the $1 trillion overpayment number matters to your premium, not just the deficit

MedPAC has argued for years that Medicare Advantage plans are paid more per enrollee than it would cost to cover the same person under Original Medicare — largely through risk-score coding that captures diagnoses more aggressively than fee-for-service billing does. CRFB's newer projection, built on the latest CBO baseline, puts a decade-long price tag on that gap: roughly $1 trillion in payments to MA plans above what equivalent Original Medicare coverage would cost.

That gap gets recycled into your plan's benefits. Insurers are required to return a share of excess payments as extra benefits — dental, vision, hearing, reduced drug copays, or a $0 premium. Our CMS 2027 Medicare Advantage Payment Rate Increase analysis found that when benchmark payments rise, so does the rebate dollar amount funding those perks — but the reverse is also true. When CMS or Congress tightens coding rules to close the overpayment gap, the rebate pool shrinks first, and benefit cuts show up in your plan's Annual Notice of Change before premiums ever move.

We already saw a preview of this mechanism. Our Star Ratings Overhaul coverage documented that CMS dropped 11 quality metrics from the 2026 Star ratings calculation, inflating scores across the industry and pushing more plans over the 4-star threshold that triggers bonus payments. That's the opposite direction from the overpayment-tightening CRFB is warning about — which tells you the policy is being pulled in two directions at once, and your plan's benefit package next year depends on which force wins in the next rulemaking cycle. We covered the mirror image of this tension — the lawsuit fighting to keep a plan's rating (and rebate dollars) from falling — in Medicare Advantage Star Rating Drop From 4 to 3.5 Stars.

The takeaway: the $0 premium and rich extra benefits you're looking at for 2027 are downstream of a payment formula under active political pressure. That's not a reason to avoid MA — it's a reason to re-run the comparison every single Open Enrollment instead of auto-renewing.

What the IRA actually protects — and why it's called "at stake"

The Medicare Rights Center's second piece lays out what changed because of the 2022 Inflation Reduction Act, in case you've forgotten how recent these protections are:

• The $2,000 annual out-of-pocket cap on Part D drug costs, which didn't exist before 2025.
• Medicare drug price negotiation, with the first 10 negotiated prices taking effect January 1, 2026.
• A $35/month insulin cap and $0 cost-sharing on ACIP-recommended adult vaccines.
• Manufacturer inflation rebates that penalize price increases above general inflation.

None of these are permanent fixtures in the way Part A hospital coverage is. They're statutory provisions that depend on continued funding and implementation — and the same budget conversation driving the MA overpayment debate touches drug negotiation savings, since CBO scores both programs against the same 10-year Medicare spending baseline.

Here's what the first round of negotiated prices actually looks like starting this year, based on the negotiated maximum fair prices CMS finalized for 2026:

Drug	Common use	Prior list price	2026 negotiated price
Eliquis	Blood thinner	~$521/month	~$231/month
Jardiance	Type 2 diabetes	~$573/month	~$197/month
Xarelto	Blood thinner	~$517/month	~$197/month
Farxiga	Diabetes/heart failure	~$556/month	~$178.50/month
Entresto	Heart failure	~$628/month	~$295/month

Worked example: Linda, 68, Ohio, on Eliquis and Jardiance

Let's put real numbers on what these two policy threads mean for one beneficiary comparing her options this fall. Linda earns $95,000/year (below the IRMAA threshold in our cms_medicare_irmaa dataset, so no income surcharge), takes Eliquis and Jardiance, and is weighing a $0-premium MA-PD plan against Original Medicare + Medigap Plan G + a standalone Part D plan.

Original Medicare + Medigap Plan G + Part D:

• Part B premium: $185/month × 12 = $2,220
• Medigap Plan G premium: our medigap_rates dataset shows Ohio-area Plan G quotes clustering around $178–$210/month for a 68-year-old; using $185/month × 12 = $2,220
• Part D plan premium: ~$47/month × 12 = $564
• Part D deductible + coinsurance toward the $2,000 IRA cap: since Eliquis and Jardiance alone would run $428/month at negotiated prices (about $5,136/year pre-cap), Linda hits the $2,000 out-of-pocket cap by roughly month five and pays $0 more on drugs for the rest of the year
• Remaining Part B deductible exposure: ~$257 (Plan G covers everything else)
• Total: ~$5,261/year, with essentially no exposure if she's hospitalized

$0-premium Medicare Advantage PPO with embedded Part D:

• Premium: $0
• Same $2,000 IRA-mandated Part D out-of-pocket cap applies — but only if her drugs aren't reclassified to a higher tier or hit with prior authorization. Our Part D Formulary Trap analysis found tier reassignments are common at plan-year rollover, and OIG data referenced in our 95% Overturn coverage shows the vast majority of MA drug denials get reversed on appeal — but only after weeks of full-price payments while she waits
• PCP/specialist copays: roughly $30–$50 per visit, call it $400/year
• If no hospitalization: total roughly $2,400/year — clearly cheaper than the Medigap path
• If Linda has one hospital stay: MOOP exposure of $4,900–$8,850 kicks in, and her total for that year could exceed $9,000 — nearly double the Medigap route

This is the core tension the $1 trillion overpayment debate and the IRA cap are both pressing on from opposite sides: the $2,000 cap has narrowed the drug-cost gap between MA and Medigap dramatically compared to pre-2025 math, which makes MA's $0 premium look more attractive in a low-utilization year. But MA's uncapped medical cost-sharing up to the MOOP — and the political uncertainty around whether next year's rebate-funded extra benefits survive a tighter overpayment crackdown — means the Medigap path still wins in any year with a major hospitalization or a plan-year formulary surprise. This is the kind of analysis Toravine runs for you, using your actual drug list, your county's Medigap rate filings, and your income bracket, so you're not building this spreadsheet from scratch every October.

The administrative risk you probably haven't priced in

Two recent settlements are worth a beneficiary's attention, even though they're not premium math. DaVita, the dialysis provider serving a Medicare-heavy population, agreed to pay $15 million to settle claims from a 2024 data breach, according to Healthcare Dive. Separately, McKesson — a major healthcare distributor — confirmed data theft in a cyberattack involving third-party apps. Neither incident changes your premium, but both are reminders that the administrative side of your care — claims processing, pharmacy records, dialysis billing — runs through vendors with their own cybersecurity track record. If you're on dialysis or use a mail-order pharmacy tied to a large distributor, it's worth checking your Medicare Summary Notices and Explanation of Benefits a little more carefully this year, the same way you'd check a formulary change.

What to actually check before you re-enroll

1. Pull your current plan's 2027 Annual Notice of Change the moment it arrives and compare the drug tier placement for everything you take against this year's list — not just the premium.
2. Confirm whether your income puts you near an IRMAA bracket. Our cms_medicare_irmaa dataset shows these thresholds are adjusted annually, and crossing one by even $1,000 in reported income adds a real surcharge on top of everything above.
3. Re-quote Medigap Plan G in your ZIP code. Rates in our medigap_rates dataset vary meaningfully by state and by insurer even for identical coverage — a filing you haven't compared since your Initial Enrollment window may no longer be the cheapest option.
4. Ask whether your MA plan's rebate-funded extras are new or shrinking. If your plan's Star rating moved, that's your first clue.

If you're turning this analysis over on your own kitchen table, you can model it for your specific situation — your drugs, your ZIP code, your income — at Toravine before the window closes on December 7.

Sources

• Evidence of MA Overpayment Continues to Mount — Medicare Rights Center
• What’s at Stake in 2026: The Inflation Reduction Act — Medicare Rights Center
• DaVita agrees to pay $15M to settle claims from data breach — Healthcare Dive
• McKesson confirms data theft in cyberattack involving third-party apps — Healthcare Dive
• Johns Hopkins Health Plans taps interim CEO as it searches for successor — Healthcare Dive